Injective Price Eyes $100 After INJ Goes Live on Solana Network
- INJ traded near $5.64 as momentum recovered from July lows.
- Solana access expands through Sunrise and LayerZero OFT infrastructure.
- A close above $6.50 could expose $7 and then $8.
Injective price traded near $5.64 after gaining more than 4%, extending its recovery from July lows near $4.00. The INJ token is now available on Solana through Sunrise and LayerZero infrastructure. The expansion gives Solana users access to INJ across supported applications. Technical momentum remains constructive, although resistance between $6.00 and $6.50 still limits the rebound.
Injective Price Tests Resistance as Recovery Momentum Builds
The daily setup shows INJ peaked above $7.50 in early June before entering a steep decline. Price bottomed during July, then rebounded toward $6.50 in late August. A later pullback returned the token toward its current range.
RSI stands at 52.76, signalling neutral-to-slightly-bullish momentum after retreating from overbought territory. Immediate support sits between $5.00 and $5.20. A loss of $5.00 could expose $4.50.
Injective price needs a daily close above $6.50 to confirm further recovery. That move could first target $7.00 and then $8.00. Crypto Patel also identified longer-term levels at $15, $31, $53, and $100, but those remain speculative.
The analyst said INJ had risen 177% from his earlier accumulation zone. That performance is specific to his stated entry range, not the wider market. Reaching $100 would require gains exceeding 1,600% from current prices, highlighting the target’s long-term and highly uncertain nature.
Solana Expansion Broadens Injective Price Utility and Access
Injective said INJ is officially live on Solana, allowing users to access the asset through supported applications. Developers can also launch tokens paired with INJ.
Injective price still depends on technical confirmation rather than the integration alone. Holding $5.00-$5.20 keeps recovery intact, while $6.50 remains the decisive barrier. A breakout would place $8 in focus before higher targets become relevant.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After Eli Lilly's nearly 300% surge in four years, Wall Street remains bullish: The "hidden pipeline" beyond GLP-1 is underestimated
Eli Lilly’s share price has surged nearly 300% since the approval of its first GLP-1 drug, with its market capitalization surpassing 1 trillion USD, yet Wall Street remains optimistic about its continued growth. Berenberg has upgraded Eli Lilly’s rating to “Buy," believing that Mounjaro and Zepbound will continue to see strong volume, and that the oral GLP-1 drug could further drive demand. Additionally, Eli Lilly continues to expand into areas such as cancer and sleep disorders, and the potential of its non-obesity-related pipelines remains underestimated by the market.
BUZZ — U.S. Stock Market News: CoreWeave, StubHub, Ultragenyx
Goldman Sachs: The industrial sector is "even more expensive" than tech stocks; global sector pricing logic is changing
The 12-month forward price-to-earnings ratio of the industrial sector has now surpassed that of the technology sector, indicating that the relative valuations among various sectors in global stock markets are undergoing a shift.
